Abstract:Immune checkpoint inhibitors have altered the treatment paradigm of small cell lung cancer (SCLC). However, the current immunotherapies, such as programmed cell death‐1 (PD‐1)/programmed death ligand 1 (PD‐L1) and cytotoxic T lymphocyte‐associated antigen‐4 (CTLA‐4), brought limited benefits to survival. It is urgent to develop new targets or immunotherapy drugs. This review focuses on multiple new targets of immunotherapy investigated in the field of SCLC, including delta‐like ligand 3 (DLL3), T cell immunoglobulin and immunoreceptor tyrosine‐based inhibitory motif structural domains (TIGIT), lymphocyte activation gene‐3 (LAG‐3), and disialoganglioside (GD2), and others. Small cell lung cancer (SCLC) is one of the highly aggressive malignancies characterized by rapid growth and early metastasis, but treatment options are limited. For SCLC, carboplatin or cisplatin in combination with etoposide chemotherapy has been considered the only standard of care, but the standard first‐line treatment only results in 10‐month survival. The majority of patients relapse within a few weeks to months after treatment, despite the relatively sensitive response to chemotherapy. Over the past decade, immunotherapy has made significant progress in the treatment of SCLC patients. However, there have been limited improvements in survival rates for SCLC patients with the current immune checkpoint inhibitors PD‐1/PD‐L1 and CTLA‐4. In the face of high recurrence rates, small beneficiary populations, and low survival benefits, the exploration of new targets for key molecules and signals in SCLC and the development of drugs with novel mechanisms may provide fresh hope for immunotherapy in SCLC. Therefore, the aim of this review was to explore four new targets, DLL3, TIGIT, LAG‐3, and GD2, which may play a role in the immunotherapy of SCLC to find useful clues and strategies to improve the outcome for SCLC patients.

Novel immunotherapeutic approaches in lung cancer: driving beyond programmed death-1/programmed death ligand-1 and cytotoxic T-lymphocyte-associated Protein-4

New progress in immunotherapy of lung cancer

Novel Immunotherapeutics for the Treatment of Non-Small Cell Lung Cancer (NSCLC) Resistant to PD-1/PD-L1 Inhibitors

The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)

A review of recent advances in the novel therapeutic targets and immunotherapy for lung cancer

Immunotherapy for Non-small-cell Lung Cancer: Current Status and Future Obstacles

Lung cancer immunotherapy: progress, pitfalls, and promises

Immunotherapy for advanced non-small cell lung cancer with negative programmed death-ligand 1 expression: a literature review

Novel cytotoxic drugs in advanced nonsmall cell lung cancer

Recent Advances in Neoantigen Vaccines for Treating Non‐small Cell Lung Cancer

Anti–PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy

Immunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept

New Immunotherapy and Lung Cancer

Recent Advances and Challenges of Immune Checkpoint Inhibitors in Immunotherapy of Non-Small Cell Lung Cancer

Immunotherapy-chemotherapy combinations for non-small cell lung cancer: current trends and future perspectives

Dendritic cell-based immunotherapy in non-small cell lung cancer: a comprehensive critical review

Recent advances and remaining challenges in lung cancer therapy

Advances in new targets for immunotherapy of small cell lung cancer

Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer

Immunotherapeutics in lung cancers: from mechanistic insight to clinical implications and synergistic perspectives

The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer